A two-component drug delivery system using Her-2-targeting thermosensitive liposomes

References

• TL Andresen, SS Jensen, and K Jørgensen. (2005). Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release. Prog Lipid Res 44:68–97.
   PubMed Web of Science ®Google Scholar
• E Azambuja, V Durbecq, DD Rosa, M Colozza, D Larsimont, M Piccart-Gebhart, and F Cardoso. (2008). HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. Ann Oncol 19:223–232.
   PubMed Web of Science ®Google Scholar
• M Benveniste, J Schlessinger, and Z Kam. (1989). Characterization of internalization and endosome formation of epidermal growth factor in transfected NIH-3T3 cells by computerized image-intensified three-dimensional fluorescence microscopy. J Cell Biol 109:2105–2115.
   PubMed Web of Science ®Google Scholar
• O Canoz, M Ozkan, V Arsav, O Er, HS Coskun, S Soyuer, and M Altinbas. (2006). The role of c-erbB-2 expression on the survival of patients with small-cell lung cancer. Lung 184:267–272.
   PubMed Web of Science ®Google Scholar
• B D'Souza, F Berdichevsky, N Kyprianou, and J Taylor-Papadimitriou. (1993). Collagen-induced morphogenesis and expression of the alpha 2-integrin subunit is inhibited in c-erbB2-transfected human mammary epithelial cells. Oncogene 8:1797–1806.
   PubMed Web of Science ®Google Scholar
• K Demura, S Morikawa, K Murakami, K Sato, H Shiomi, S Naka, Y Kurumi, T Inubushi, and T Tani. (2006). An easy-to-use microwave hyperthermia system combined with spatially resolved MR temperature maps: Phantom and animal studies. J Surg Res 135:179–186.
   PubMed Web of Science ®Google Scholar
• CJ Diederich. (2005). Thermal ablation and high-temperature thermal therapy: Overview of technology and clinical implementation. Int J Hyperthermia 21:745–753.
   PubMed Web of Science ®Google Scholar
• RH Engel, and VG Kaklamani. (2007). HER2-positive breast cancer: Current and future treatment strategies. Drugs 67:1329–1341.
   PubMed Web of Science ®Google Scholar
• E Friedländer, M Barok, J Szöllosi, and G Vereb. (2008). ErbB-directed immunotherapy: Antibodies in current practice and promising new agents. Immunol Lett 116:126–140.
   PubMed Web of Science ®Google Scholar
• D Haemmerich, and PF Laeseke. (2005). Thermal tumour ablation: Devices, clinical applications and future directions. Int J Hyperthermia 21:755–760.
   PubMed Web of Science ®Google Scholar
• HD Han, MS Choi, T Hwang, CK Song, H Seong, TW Kim, HS Choi, and BC Shin. (2006). Hyperthermia-induced antitumor activity of thermosensitive polymer modified temperature-sensitive liposomes. J Pharm Sci 95:1909–1917.
   PubMed Web of Science ®Google Scholar
• ML Hauck, SM LaRue, WP Petros, JM Poulson, D Yu, I Spasojevic, AF Pruitt, A Klein, B Case, DE Thrall, D Needham, and MW Dewhirst. (2006). Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clin Cancer Res 12:4004–4010.
   PubMed Web of Science ®Google Scholar
• DM Haynik, AA Roma, and RA Prayson. (2007). HER-2/neu expression in glioblastoma multiforme. Appl Immunohistochem Mol Morphol 15:56–58.
   PubMedGoogle Scholar
• T Hosokawa, M Sami, Y Kato, and E Hayakawa. (2003). Alteration in the temperature-dependent content release property of thermosensitive liposomes in plasma. Chem Pharm Bull 51:1227–1232.
   PubMed Web of Science ®Google Scholar
• M Hossann, M Wiggenhorn, A Schwerdt, K Wachholz, N Teichert, H Eibl, RD Issels, and LH Lindner. (2007). In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes. Biochim Biophys Acta 1768:2491–2499.
   PubMed Web of Science ®Google Scholar
• MR Jalali Nadoushan, T Taheri, N Jouian, and F Zaeri. (2007). Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder. Urology 4:151–154.
   Google Scholar
• JB Johnston, S Navaratnam, MW Pitz, JM Maniate, E Wiechec, H Baust, J Gingerich, GP Skliris, LC Murphy, and M Los. (2006). Targeting the EGFR pathway for cancer therapy. Curr Med Chem 13:3483–3492.
   PubMed Web of Science ®Google Scholar
• K Kakinuma, R Tanaka, H Takahashi, Y Sekihara, M Watanabe, and M Kuroki. (1996). Drug delivery to the brain using thermosensitive liposome and local hyperthermia. Int J Hyperthermia 12:157–165.
   PubMed Web of Science ®Google Scholar
• G Kong, RD Braun, and MW Dewhirst. (2000). Hyperthermia enables tumor-specific nanoparticle delivery: Effect of particle size. Cancer Res 60:4440–4445.
   PubMed Web of Science ®Google Scholar
• G Kong, RD Braun, and MW Dewhirst. (2001). Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 61:3027–3032.
   PubMed Web of Science ®Google Scholar
• EB Kullberg, M Nestor, and L Gedda. (2003). Tumor-cell targeted epidermal growth factor liposomes loaded with boronated acridine: Uptake and processing. Pharm Res 20:229–236.
   PubMed Web of Science ®Google Scholar
• M Kullberg, K Mann, and JL Owens. (2005). Improved drug delivery to cancer cells: A method using magnetoliposomes that target epidermal growth factor receptors. Med Hypotheses 64:468–470.
   PubMed Web of Science ®Google Scholar
• D Needham, G Anyarambhatla, G Kong, and MW Dewhirst. (2000). A new temperature-sensitive liposome for use with mild hyperthermia: Characterization and testing in a human tumor xenograft model. Cancer Res 60:1197–1201.
   PubMed Web of Science ®Google Scholar
• Y Nishio, Y Yamada, H Kokubo, K Nakamura, S Aoki, T Taki, N Honda, A Nakagawa, S Saga, and K Hara. (2006). Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology 68:110–115.
   PubMed Web of Science ®Google Scholar
• JW Park, DB Kirpotin, K Hong, R Shalaby, Y Shao, UB Nielsen, JD Marks, D Papahadjopoulos, and CC Benz. (2001). Tumor targeting using anti-her2 immunoliposomes. J Control Release 74:95–113.
   PubMed Web of Science ®Google Scholar
• AM Ponce, Z Vujaskovi, F Yuan, D Needham, and MW Dewhirst. (2006). Hyperthermia mediated liposomal drug delivery. Int J Hyperthermia 22:205–213.
   PubMed Web of Science ®Google Scholar
• CJ Provoda, EM Stier, and KD Lee. (2003). Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin. J Biol Chem 278:35102–35108.
   PubMed Web of Science ®Google Scholar
• G Scherphof, F Roerdink, M Waite, and J Parks. (1978). Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. Biochim Biophys Acta 542:296–307.
   PubMed Web of Science ®Google Scholar
• PK Smith, RI Krohn, GH Hermanson, AK Mallia, FH Gartner, MD Provenzano, EK Fujimoto, NM Goike, BJ Olson, and DK Klenk. (1985). Measurement of protein using bicinchoninic acid. Anal Biochem 150:76–85.
   PubMed Web of Science ®Google Scholar
• PR Stauffer. (2005). Evolving technology for thermal therapy of cancer. Int J Hyperthermia 21:731–744.
   PubMed Web of Science ®Google Scholar
• VP Torchilin, and V Weissig. (2003). Liposomes. Oxford: University Press. p 34–35.
   Google Scholar
• H Wartlick, K Michaelis, S Balthasar, K Strebhardt, J Kreuter, and K Langer. (2004). Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target 12:461–471.
   PubMed Web of Science ®Google Scholar
• Q Wei, EB Kullberg, and L Gedda. (2003). Trastuzumab-conjugated boron-containing liposomes for tumor-cell targeting; development and cellular studies. Int J Oncol 23:1159–1165.
   PubMed Web of Science ®Google Scholar
• R Worthylake, LK Opresko, and HS Wiley. (1999). ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 274:8865–8874.
   PubMed Web of Science ®Google Scholar
• T Yang, MK Choi, FD Cui, JS Kim, SJ Chung, CK Shim, and DD Kim. (2007). Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 120:169–177.
   PubMed Web of Science ®Google Scholar